Lead Product(s) : INV-101
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Innovo Reports Positive Phase 1 for INV-101 Targeting Autoimmune Diseases
Details : INV-101, a novel oral immuno-metabolic modulator targeting glycogen phosphorylase. It is being evaluated for the treatment of autoimmune diseases.
Product Name : INV-101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 12, 2025
Lead Product(s) : INV-101
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
